Los Angeles Capital Management LLC acquired a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,599 shares of the biotechnology company's stock, valued at approximately $151,000.

A number of other institutional investors have also added to or reduced their stakes in AVXL. Money Concepts Capital Corp bought a new position in Anavex Life Sciences in the 3rd quarter valued at about $138,000. Janney Montgomery Scott LLC bought a new position in Anavex Life Sciences during the 3rd quarter valued at $108,000. Raymond James Financial Services Advisors Inc. boosted its holdings in Anavex Life Sciences by 9.0% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 30,270 shares of the biotechnology company's stock worth $312,000 after acquiring an additional 2,500 shares during the last quarter. Foster Victor Wealth Advisors LLC grew its stake in shares of Anavex Life Sciences by 28.5% in the 3rd quarter. Foster Victor Wealth Advisors LLC now owns 26,347 shares of the biotechnology company's stock worth $291,000 after acquiring an additional 5,836 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Anavex Life Sciences by 5.5% in the second quarter. Legal & General Group Plc now owns 33,556 shares of the biotechnology company's stock valued at $336,000 after purchasing an additional 1,737 shares during the last quarter. 31.22% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Trading Up 0.4 %

Anavex Life Sciences stock opened at $10.56 on Friday. The business's 50 day simple moving average is $9.66 and its 200 day simple moving average is $10.49. Anavex Life Sciences Corp. has a 12 month low of $7.13 and a 12 month high of $15.24. The company has a market cap of $823.26 million, a price-to-earnings ratio of -17.03 and a beta of 0.69.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AVXL. HC Wainwright upped their price objective on shares of Anavex Life Sciences from $42.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, January 3rd. Cantor Fitzgerald lowered Anavex Life Sciences from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $16.00 to $11.00 in a report on Tuesday, December 6th. StockNews.com assumed coverage on Anavex Life Sciences in a research report on Wednesday, October 12th. They set a "sell" rating for the company. Finally, Jonestrading boosted their price target on shares of Anavex Life Sciences from $40.00 to $80.00 in a report on Friday, December 2nd.

Anavex Life Sciences Profile

(Get Rating)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.

Featured Stories

• Get a free copy of the StockNews.com research report on Anavex Life Sciences (AVXL)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.